胸部肿瘤基础科学二十年进展及其转化影响
本文总结2005至2025年间肺癌、间皮瘤和胸腺上皮恶性肿瘤的基础科学转化进展,由多学科胸部肿瘤专家共同完成。重点阐述基础科学如何改善这些癌症的诊断、预后和治疗,包括PD-L1作为免疫标志物指导免疫治疗、肺癌一级亲属风险升高85%、以及BAP1等胚系突变相关间皮瘤新亚型等特点。胸腺上皮肿瘤进展相对较少,但生物学认识已促成临床相关干预。
要点
- 肺癌一级亲属患病风险高85%,提示家族成员可能从早期筛查中获益。
- PD-L1水平已作为免疫标志物指导免疫治疗应用。
- BAP1等胚系突变相关间皮瘤亚型侵袭性更低、治疗反应更好,适合筛查。
核心结论
- 过去20年认识到肺癌是组织学、免疫和基因组差异巨大的疾病集合,影响预后和治疗反应。
- 基础科学的转化进展已改善肺癌、间皮瘤和胸腺上皮肿瘤的诊断、预后和治疗。
- 间皮瘤应转向个体化治疗而非「一刀切」模式。
研究设计与样本
- 由多学科胸部肿瘤专家共同撰写的综述,总结2005至2025年肺癌、间皮瘤和胸腺上皮恶性肿瘤的进展。
主要发现
- 肺癌一级亲属发生肺癌的风险高85%。
- PD-L1水平被用作指导免疫治疗的免疫标志物。
- 在BAP1等抑癌基因失活胚系突变携带者中发现了不同变异的间皮瘤,包括由融合基因引起的新变异。
- 这些间皮瘤变异具有特定组织学和分子遗传学改变,患者肿瘤侵袭性通常更低且对治疗更敏感。
- 胸腺上皮肿瘤进展较少,但生物学新认识已促成临床相关干预开发。
关键数值与推荐
- 肺癌一级亲属患病风险高85%。
- PD-L1水平作为免疫标志物指导免疫治疗使用。
- BAP1等抑癌基因失活杂合胚系突变携带者中识别出间皮瘤不同变异。
临床怎么用
- 肺癌患者一级亲属可能从早期肺癌筛查项目中获益。
- PD-L1水平可用于指导肺癌免疫治疗决策。
- 对BAP1等胚系突变携带者应考虑筛查多种恶性肿瘤。
- 间皮瘤治疗应根据组织学和分子遗传学改变进行个体化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this article, we summarize the progress made in lung cancer, mesothelioma, and thymic epithelial malignancy during the period 2005-2025. We enlisted multidisciplinary thoracic oncologic experts to tackle this task. The main focus of the article concerns how basic science with translational impact has improved the diagnosis, prognosis, and therapy of these cancers. During the past 20 years, we have come to the realization that "lung cancer" is a name that encompasses tumors with vast histologic, immune, and genomic differences that in turn influence prognosis and response to therapy. For example, programmed death-ligand 1 levels are being used as an immune signature which guides the use of immunotherapy. There is an 85% higher risk for developing lung cancer among first-degree relatives of patients with lung cancer. Accordingly, an increasing number of lung cancers are being identified in carriers of predisposing germline pathogenic inactivating mutations, suggesting that screening programs for early lung cancer detection may benefit family members. Underscoring the role of genetics, and the importance of germline testing, a different variant of mesothelioma has been identified developing in carriers of inactivating heterozygous germline mutations of BAP1 and of other tumor suppressor genes, including a new variant of mesothelioma caused by fusion genes. These variants of mesothelioma are characterized by specific histologic and molecular genetic alterations. These patients benefit from screening programs as they are at risk of multiple malignancies, their tumors are usually much less aggressive, and they are more responsive to therapy compared with sporadic, asbestos-induced mesotheliomas. Thus, the tailored therapeutic approach that is described here for lung cancer may extend to patients with mesothelioma, rather than the previous "one therapy fits all" approach. Progress in the rare thymic epithelial tumors has been less marked; however, recent insights into the biology of thymic tumors have resulted in the development of clinically relevant interventions.
引用
- Carbone M, Amos C, Attanoos RL, et al. Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact. J Thorac Oncol. 2026. PMID: 41519536. doi:10.1016/j.jtho.2025.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。